Research Summary

Selected Publications

• 1. Hashimoto M, Saito Y, Nakagawa R, Ogahara I, Takagi S, Takata S, Amitani H, Endo M, Yuki H, Jordan A. Ramilowski, Jessica Severin, Manabe R, Watanabe T, Ozaki K, Kaneko A, Kajita H, Fujiki S, Sato K, Honma T, Uchida N, Fukami T, Okazaki Y, Ohara O, Leonard D. Shultz, Yamada M, Taniguchi S, Paresh Vyas, Michiel de Hoon, Momozawa Y, Ishikawa F.:
  "Maximal Therapeutic Vulnerability Converges on XIAP and BCL2 in Aggressive Acute Myeloid Leukemia with Diverse Genetic Aberrations."
  Nature Cancer, 340-356, 2021
• 2.Saito Y, Shultz LD, Ishikawa F.:
  "Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice"
  Trends Immunol. 2020 Aug;41(8):706-720.
• 3.Saito Y, Mochizuki Y, Ogahara I, Watanabe T, Hogdal L, Takagi S, Sato K, Kaneko A, Kajita H, Uchida N, Fukami T, Shultz LD, Taniguchi S, Ohara O, Letai AG, Ishikawa F.:
  "Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways"
  Science Translational Medicine eaao1214, 2017.
• 4.Saito Y, Yuki H, Kuratani M, Hashizume Y, Takagi S, Honma T, Tanaka A, Shirouzu M, Mikuni J, Handa N, Ogahara I, Sone A, Najima Y, Tomabechi Y, Wakiyama M, Uchida N, Tomizawa-Murasawa M, Kaneko A, Tanaka S, Suzuki N, Kajita H, Aoki Y, Ohara O, Shultz LD, Fukami T, Goto T, Taniguchi S, Yokoyama S and Ishikawa F.:
  "A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivor"
  Sci Transl Med 5, 181ra52, 2013.
• 5.Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa-Murasawa M, Doi T, Sone A, Suzuki N, Fujiwara H, Yasukawa M, Ishikawa F.:
  "Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγnull humanized mice."
  Proc Natl Acad of Sci U S A 107, 13022-7, 2010.
• 6.Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, Taniguchi S, Shultz LD, Ishikawa F.:
  "Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML"
  Nat Biotechnol 28, 275-80, 2010.
• 7.Saito Y, KitamuraH, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, Uchida N, Suzuki N, Sone A, Najima Y, Ozawa H, Wake A, Taniguchi S, Shultz LD, Ohara O, Ishikawa F.:
  "Identification for therapeutic targets for quiescent chemotherapy-resistant human AML stem cells"
  Sci Transl Med 2, 17ra9, 2010.
• 8.Ishikawa F, Yoshika S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, Ohara O, Akashi K, Harada M, Shultz LD.:
  "Chemotherapy-resistant human AML stem cells home to and engraft within the bone marrow endosteal region"
  Nat Biotechnol 25, 1315-21, 2007.
• 9.Shultz LD, Ishikawa F, Greiner DL.:
  "Humanized mice in translational biomedical research"
  Nat Rev Immunol 7, 118-30, 2007.

Recent Research Results

• 

  Jun. 28, 2021
  Precision-medicine approach turns up novel drug combination for aggressive leukemias

• 

  Oct. 26, 2017
  Blocking key pathways is a way to defeat cancer cells

• 

  Jun. 21, 2013
  A drug lead for leukemia

• 

  Apr. 18, 2013
  Compound that could prevent acute blood cancer relapse identified

Related Links

Lab Members

Contact Information

1-7-22 Suehiro-cho, Tsurumi-ku,
Yokohama City, Kanagawa,
230-0045, Japan
Tel: +81-(0)45-503-9448
Fax: +81-(0)45-503-7068
Email: fumihiko.ishikawa [at] riken.jp